Blood metabolomic profile in patients with type 2 diabetes mellitus with diabetic peripheral neuropathic pain

Hung‐Chou Kuo,Chia‐Ni Lin,Sung‐Sheng Tsai,Chiung‐Mei Chen,Rong‐Kuo Lyu,Chun‐Che Chu,Long‐Sun Ro,Ming‐Feng Liao,Hong‐Shiu Chang,Yi‐Ching Weng,Jawl‐Shan Hwang
DOI: https://doi.org/10.1111/jdi.14355
2024-11-23
Journal of Diabetes Investigation
Abstract:Glutamate and several phosphatidylcholine (PC) were identified as potential metabolic markers for diabetic peripheral neuropathic pain (DPNP) in type 2 diabetes mellitus patients. Glycemic indices did not differ between type 2 diabetes mellitus patients with and without DPNP, suggesting that metabolic alterations beyond glycemic control may play a role in DPNP. Aims This study aimed to identify metabolic markers for diabetic peripheral neuropathic pain (DPNP) in patients with type 2 diabetes mellitus (T2DM). Materials and Methods Blood metabolite levels in the amino acid, biogenic amine, sphingomyelin, phosphatidylcholine (PC), carnitines, and hexose classes were analyzed in nondiabetic control (n = 27), T2DM without DPNP (n = 58), and T2DM with DPNP (n = 29) using liquid chromatography tandem mass spectrometry. Variable importance projection (VIP) evaluation by partial least squares discriminant analysis was performed on clinical parameters and metabolites. Results Sixteen variables with VIP > 1.0 (P
endocrinology & metabolism
What problem does this paper attempt to address?